School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Education section navigation

  • Educational Programs
    • Sub link
      Doctor of Medicine (MD)
    • Sub link
      MD and Bioethics (MA) Dual Degree
    • Sub link
      MD and Public Health (MPH) Dual Degree
    • Sub link
      MD and Master of Science in Clinical Research (MSCR) Dual Degree
    • Sub link
      MD and Business (MBA) Dual Degree
    • Sub link
      Education Transformation
  • Admissions
    • Sub link
      Visiting Medical Students
    • Sub link
      International Students
  • Cost and Financial Aid
  • Resources
    • Sub link
      Center for Holistic Student Success
    • Sub link
      Office of Multicultural Affairs
    • Sub link
      Academic Advising
    • Sub link
      Registrar
  • Residencies and Fellowships
    • Sub link
      Programs
    • Sub link
      Housestaff
    • Sub link
      Wellness
    • Sub link
      Diversity
  • Office of Postdoctoral and Mentored Trainee Education (OPMTE)
    • Sub link
      FIRST IRACDA Program
    • Sub link
      Prospective Postdocs
    • Sub link
      Career and Professional Development
    • Sub link
      Training Programs at Emory
    • Sub link
      Featured Alumni
  • Office of Multicultural Affairs
    • Sub link
      Meet Our Team
    • Sub link
      Emory Pipeline Collaborative
    • Sub link
      Emory Premedical Readiness Engagement Program
    • Sub link
      EMPACT Mentoring Program
    • Sub link
      HealthPREP
    • Sub link
      HCOP Ambassadors
    • Sub link
      Summer Science Academy
    • Sub link
      OMA Events
    • Sub link
      Diversity, Equity & Inclusion for Residents & Fellows
  • Emory School of Medicine Simulation Program
    • Sub link
      Work with ExCEL
    • Sub link
      Simulation Program
  • Medical Scientist Training Program (MD/PhD)
    • Sub link
      Welcome
    • Sub link
      Who we are
    • Sub link
      Our Program
    • Sub link
      Admissions
    • Sub link
      Donate to MD/PhD Program
  • Center for Holistic Student Success
    • Sub link
      Academic Support
    • Sub link
      Well-being Resources
    • Sub link
      EmoryDOCS
    • Sub link
      Mental Health and Wellness
  • Center for Humanizing Innovations in Medical Education

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Education

Profile

Mary Lechowicz MD

  • Department of Hematology and Medical Oncology
    Professor
  • (404) 778-1900
  • mlechow@emory.edu
Head shot of Mary Lechowicz

Academic Appointment

  • Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine

Education

Degrees

  • MD from State University of New York, New York
  • BA from Hofstra University, Hempstead

Research

Focus

  • My research focus is virally-related and T -cell lymphomas through clinical trial design, implementation, and correlative research with basic scientists. These populations are rare diseases with less emphasis on clinical research and standard of care options. I develop collaborations throughout the country to improve awareness, outcomes, and knowledge about these diseases.

Publications

  • Characterizing the heterogeneity of Castleman disease and oligocentric subtype: findings from the ACCELERATE registry.
    Blood Adv Volume: 9 Page(s): 1952 - 1965
    04/22/2025 Authors: Pierson SK; Brandstadter JD; Torigian DA; Bagg A; Lechowicz MJ; Alapat D; Casper C; Chadburn A; Chandrakasan S; Dispenzieri A
  • ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Szary Syndrome.
    Transplant Cell Ther Volume: 30 Page(s): 1047 - 1060
    11/01/2024 Authors: Goyal A; O'Leary D; Dabaja B; Weng W-K; Zain J; Cutler C; Guitart J; Kim YH; Geskin LJ; Hoppe RT
  • Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease.
    Haematologica Volume: 109 Page(s): 2196 - 2206
    07/01/2024 Authors: Bustamante MS; Pierson SK; Ren Y; Bagg A; Brandstadter JD; Srkalovic G; Mango N; Alapat D; Lechowicz MJ; Li H
  • Allogeneic hematopoietic stem cell transplantation after mogamulizumab in T-cell lymphoma patients: a retrospective analysis.
    Int J Hematol Volume: 119 Page(s): 736 - 744
    06/01/2024 Authors: Lechowicz MJ; Smith C; Ristuccia R; Dwyer K
  • Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.
    Haematologica Volume: 109 Page(s): 209 - 219
    01/01/2024 Authors: Iyer SP; Huen A; Ai WZ; Jagadeesh D; Lechowicz MJ; Okada C; Feldman TA; Ghione P; Alderuccio JP; Champion R
  • Cutaneous T-cell lymphoma with CNS involvement: a case series and review of the literature.
    CNS Oncol Volume: 12 Page(s): CNS105
    12/01/2023 Authors: Preston JD; Jansen CS; Kosaraju S; Niyogusaba T; Zhuang TZ; Iwamoto SW; Hutto SK; Lechowicz MJ; Allen PB
  • Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
    Blood Adv Volume: 7 Page(s): 6652 - 6664
    11/14/2023 Authors: Pierson SK; Lim MS; Srkalovic G; Brandstadter JD; Sarmiento Bustamante M; Shyamsundar S; Mango N; Lavery C; Austin B; Alapat D
  • Ongoing symptoms following complete surgical excision in unicentric Castleman disease.
    Am J Hematol Volume: 98 Page(s): E334 - E337
    11/01/2023 Authors: Sarmiento Bustamante M; Shyamsundar S; Coren FR; Bagg A; Srkalovic G; Alapat D; van Rhee F; Lim MS; Lechowicz MJ; Brandstadter JD
  • Characterizing Outcomes in Visceral Cutaneous T-Cell Lymphoma: A Single Center Retrospective Study.
    Clin Lymphoma Myeloma Leuk Volume: 23 Page(s): 667 - 673
    09/01/2023 Authors: Zhuang TZ; McCook-Veal A; Switchenko J; Niyogusaba T; Tarabadkar ES; Baird K; O'Leary C; Paulino D; Lechowicz MJ; Allen PB
  • Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.
    Br J Haematol Volume: 202 Page(s): 525 - 529
    08/01/2023 Authors: Stuver R; Horwitz SM; Advani RH; Vose JM; Lee HJ; Mehta-Shah N; Zain JM; Haverkos B; Lechowicz MJ; Moskowitz AJ
  • Mitigation strategies among cutaneous T-cell lymphoma patients with positive Staphylococcus aureus skin and soft tissue cultures have unclear impacts on the risk of subsequent bacteremia.
    Leuk Lymphoma Volume: 64 Page(s): 597 - 604
    03/01/2023 Authors: Allen PB; Goyal S; Switchenko J; Tarabadkar E; Pouch S; Parikh P; Palmer A; Martini D; Kim E; Lechowicz MJ
  • Staging lymph nodes and blood at diagnosis in mycosis fungoides identifies patients at increased risk of progression to advanced stage: A retrospective cohort study.
    Cancer Volume: 129 Page(s): 541 - 550
    02/15/2023 Authors: Allen PB; McCook-Veal AA; Switchenko JM; Paulino DM; Niyogusaba T; Baird KM; Tarabadkar ES; Lechowicz MJ
  • Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
    Cancer Res Commun Volume: 2 Page(s): 1684 - 1692
    12/01/2022 Authors: Chang A; Akhtar A; Lai L; Orellana-Noia VM; Linderman SL; McCook-Veal AA; Switchenko JM; Saini M; Valanparambil RM; Blum KA
  • Clinical Presentation and Outcome Differences Between Black Patients and Patients of Other Races and Ethnicities With Mycosis Fungoides and Szary Syndrome.
    JAMA Dermatol Volume: 158 Page(s): 1293 - 1299
    11/01/2022 Authors: Allen PB; Goyal S; Niyogusaba T; O'Leary C; Ayers A; Tarabadkar ES; Khan MK; Lechowicz MJ
  • CLL-515 Antibody Responses Against SARS-CoV-2 Variants after Booster Vaccination in Patients With B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia.
    Clin Lymphoma Myeloma Leuk Volume: 22 Suppl 2 Page(s): S281 - S282
    10/01/2022 Authors: Chang A; Lai L; Akhtar A; Linderman S; Orellana-Noia V; Saini M; Valanparambil R; Blum K; Allen P; Lechowicz M
  • African American and Caucasian patients with Szary syndrome have no differences in outcomes at an ethnically diverse urban medical center.
    Leuk Lymphoma Volume: 63 Page(s): 2094 - 2101
    09/01/2022 Authors: Martini DJ; Goyal S; Switchenko JM; Lechowicz MJ; Allen PB
  • Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC.
    Blood Volume: 140 Page(s): 419 - 437
    08/04/2022 Authors: Olsen EA; Whittaker S; Willemze R; Pinter-Brown L; Foss F; Geskin L; Schwartz L; Horwitz S; Guitart J; Zic J
  • The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.
    Br J Haematol Volume: 198 Page(s): 307 - 316
    07/01/2022 Authors: Fajgenbaum DC; Pierson SK; Kanhai K; Bagg A; Alapat D; Lim MS; Lechowicz MJ; Srkalovic G; Uldrick TS; van Rhee F
  • Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma.
    Ann Hematol Volume: 101 Page(s): 335 - 340
    02/01/2022 Authors: Krishnan M; Bociek RG; Fanale M; Iyer SP; Lechowicz MJ; Bierman PJ; Armitage JO; Lunning M; Kallam A; Vose JM
  • Racial differences in clinical presentation and outcomes in mycosis fungoides and Szary syndrome in the United States: a large singe center retrospective analysis.
    Eur J Cancer Volume: 156 Suppl 1 Page(s): S34
    10/01/2021 Authors: Allen PB; Goyal S; O'Leary C; Ayers A; Niyogusaba T; Khan MK; Lechowicz MJ
  • T-Cell Receptor Gene Rearrangement Clonality, Flow Cytometry Status, and Associated Outcomes in Early-Stage Cutaneous T-Cell Lymphoma.
    JAMA Dermatol Volume: 157 Page(s): 954 - 962
    08/01/2021 Authors: Marks JA; Switchenko JM; Martini DJ; Tarabadkar ES; Khan MK; Lechowicz MJ; Allen PB
  • Nivolumab-associated cutaneous T-cell lymphoma.
    JAAD Case Rep Volume: 9 Page(s): 39 - 41
    03/01/2021 Authors: Marks JA; Parker DC; Garrot LC; Lechowicz MJ
  • International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
    Blood Adv Volume: 4 Page(s): 6039 - 6050
    12/08/2020 Authors: van Rhee F; Oksenhendler E; Srkalovic G; Voorhees P; Lim M; Dispenzieri A; Ide M; Parente S; Schey S; Streetly M
  • Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease.
    Am J Hematol Volume: 95 Page(s): 1553 - 1561
    12/01/2020 Authors: Fajgenbaum DC; Wu D; Goodman A; Wong R; Chadburn A; Nasta S; Srkalovic G; Mukherjee S; Leitch H; Jayanthan R
  • Evaluating Outcomes for Autologous Hematopoietic Cell Transplantation for Diffuse Large B-Cell Lymphoma in the CAR-T Era
    Volume: 136
    11/05/2020 Authors: Santapuram PR; Rupji M; Graiser M; Waller EK; Blum KA; Allen PB; Koff JL; Heffner L; Lechowicz MJ; Lonial S
  • A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma
    Volume: 136
    11/05/2020 Authors: Iyer SP; Huen A; Haverkos B; Ai WZ; Okada C; Kuzel TM; Lechowicz MJ; Alderuccio JP; Mohrbacher A; Stevens DA
  • Maintenance Therapy for Cutaneous T-cell Lymphoma After Total Skin Electron Irradiation: Evidence for Improved Overall Survival With Ultraviolet Therapy.
    Clin Lymphoma Myeloma Leuk Volume: 20 Page(s): 757 - 767.e3
    11/01/2020 Authors: Kudelka MR; Switchenko JM; Lechowicz MJ; Esiashvili N; Flowers CR; Khan MK; Allen PB
  • Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL).
    Leuk Lymphoma Volume: 61 Page(s): 2652 - 2658
    11/01/2020 Authors: Allen PB; Switchenko J; Ayers A; Kim E; Lechowicz MJ
  • Incidence of Cutaneous T Cell Lymphoma and Air Levels of Benzene and Trichloroethylene
    Volume: 95 Page(s): S13 - S13
    10/01/2020 Authors: Gandrakota N; Lechowicz M; Allen P; Ward K; Switchenko J
  • Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K / Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma.
    Cancers (Basel) Volume: 12
    08/15/2020 Authors: Huen A; Haverkos BM; Zain J; Radhakrishnan R; Lechowicz MJ; Devata S; Korman NJ; Pinter-Brown L; Oki Y; Barde PJ
  • Induction of remission in a patient with end-stage cutaneous T-cell lymphoma by concurrent use of radiation therapy, gentian violet, and mogamulizumab.
    JAAD Case Rep Volume: 6 Page(s): 761 - 765
    08/01/2020 Authors: Westergaard SA; Lechowicz MJ; Harrington M; Elsey J; Arbiser JL; Khan MK
  • Castleman disease spectrum.
    Volume: 38
    05/20/2020 Authors: Khor J; Pierson SK; Powers V; Tamakloe M-A; Gorzewski A; Floess K; Ziglar J; Haljasmaa E; Ren Y; Casper C
  • Clustering of cutaneous T-cell lymphoma is associated with increased levels of the environmental toxins benzene and trichloroethylene in the state of Georgia.
    Cancer Volume: 126 Page(s): 1700 - 1707
    04/15/2020 Authors: Clough L; Bayakly AR; Ward KC; Khan MK; Chen SC; Lechowicz MJ; Flowers CR; Allen PB; Switchenko JM
  • Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study.
    Cancer Volume: 126 Page(s): 1235 - 1242
    03/15/2020 Authors: Cohen JB; Wei L; Maddocks KJ; Christian B; Heffner LT; Langston AA; Lechowicz MJ; Porcu P; Flowers CR; Devine SM
  • Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.
    Acta Haematol Volume: 143 Page(s): 40 - 50
    01/01/2020 Authors: Lansigan F; Horwitz SM; Pinter-Brown LC; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA
  • Mortality and Risk Factors for Bacteremia in Patients with Cutaneous T-Cell Lymphoma (CTCL) at Emory University
    Volume: 134
    11/13/2019 Authors: Allen P; Kim E; Ayers A; Lechowicz MJ
  • Management of NK/T-Cell Lymphoma, Nasal Type.
    J Oncol Pract Volume: 15 Page(s): 513 - 520
    10/01/2019 Authors: Allen PB; Lechowicz MJ
  • The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
    Cancer Volume: 125 Page(s): 1507 - 1517
    05/01/2019 Authors: Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C
  • Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
    Lancet Haematol Volume: 5 Page(s): e609 - e617
    12/01/2018 Authors: Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D
  • Evaluation of Maintenance Therapy in Cutaneous T-Cell Lymphoma Patients Receiving Total Skin Electron Beam Radiation Therapy
    Volume: 132
    11/29/2018 Authors: Kudelka M; Lechowicz MJ; Khan MK; Esiashvili N; Flowers CR; Allen P
  • International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
    Blood Volume: 132 Page(s): 2115 - 2124
    11/15/2018 Authors: van Rhee F; Voorhees P; Dispenzieri A; Foss A; Srkalovic G; Ide M; Munshi N; Schey S; Streetly M; Pierson SK
  • Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
    Lancet Oncol Volume: 19 Page(s): 1192 - 1204
    09/01/2018 Authors: Kim YH; Bagot M; Pinter-Brown L; Rook AH; Porcu P; Horwitz SM; Whittaker S; Tokura Y; Vermeer M; Zinzani PL
  • Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network.
    Br J Haematol Volume: 181 Page(s): 760 - 769
    06/01/2018 Authors: Federico M; Bellei M; Marcheselli L; Schwartz M; Manni M; Tarantino V; Pileri S; Ko Y-H; Cabrera ME; Horwitz S
  • Association of insurance status and race with overall survival among patients with cutaneous T-cell lymphoma: A National Cancer DataBase analysis.
    Volume: 36
    05/20/2018 Authors: Allen PB; Flowers C; Lechowicz MJ; Goldstein J
  • Impact of individual comorbidities on post-transplant outcomes for elderly patients with non-Hodgkin lymphoma (NHL).
    Volume: 36
    05/20/2018 Authors: Ip A; Switchenko JM; Graiser M; Koff JL; Gupta VA; Lechowicz MJ; Nooka AK; Kaufman JL; Lonial S; Waller EK
  • Assessing Individual Comorbidities in Elderly Non-Hodgkin Lymphoma (NHL) Patients Undergoing Autologous Stem Cell Transplant (ASCT)
    Volume: 24 Page(s): S135 - S136
    03/01/2018 Authors: Ip A; Switchenko JM; Graiser M; Koff J; Gupta V; Lechowicz M; Al-Kadhimi Z; Nooka A; Kaufman J; Lonial S
  • STARI NIGHT: SOUTHERN TICK ASSOCIATED RASH ILLNESS AFTER AUTOLOGOUS STEM CELL TRANSPLANT
    Volume: 66 Page(s): 471 - 472
    02/01/2018 Authors: Summers N; Chai Z; Shums M; Lechowicz M; Friedman-Moraco R
  • Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas.
    Cancer Manag Res Volume: 10 Page(s): 6731 - 6742
    01/01/2018 Authors: Allen PB; Lechowicz MJ
  • Safety and Anti-Tumour Activity of RP6530, Dual PI3K delta/gamma Inhibitor, in Relapsed/Refractory T-Cell Lymphoma: Updated Results from the Dose Expansion Cohort of an on-Going Phase I/Ib Study
    Volume: 130
    12/07/2017 Authors: Oki Y; Zain J; Haverkos BM; Korman N; Pinter-Brown L; Devata S; Ramchandren R; Lechowicz MJ; Barde P; Huen ANA
  • The Role of Upfront Hematopoietic Stem Cell Transplantation (HSCT) in Peripheral T-Cell Lymphoma (PTCL) Patients in Complete Remission (CR) with a Special Focus on Nodal PTCL: Report from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE), a Prospective Multicenter Cohort Study
    Volume: 130
    12/07/2017 Authors: Park SI; Horwitz SM; Foss FM; Pinter-Brown LC; Carson KR; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C
  • Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.
    Clin Lymphoma Myeloma Leuk Volume: 17 Page(s): 193 - 200
    04/01/2017 Authors: Hsi ED; Horwitz SM; Carson KR; Pinter-Brown LC; Rosen ST; Pro B; Federico M; Gisselbrecht C; Schwartz M; Bellm LA
  • A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.
    Cancer Volume: 123 Page(s): 1174 - 1183
    04/01/2017 Authors: Carson KR; Horwitz SM; Pinter-Brown LC; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA
  • International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.
    Blood Volume: 129 Page(s): 1646 - 1657
    03/23/2017 Authors: Fajgenbaum DC; Uldrick TS; Bagg A; Frank D; Wu D; Srkalovic G; Simpson D; Liu AY; Menke D; Chandrakasan S
  • Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors.
    Bone Marrow Transplant Volume: 52 Page(s): 132 - 134
    01/01/2017 Authors: DeFilipp Z; Rosand CB; Goldstein DA; Master VA; Carthon BC; Harris WB; Kucuk O; Al-Kadhimi Z; Cohen JB; Flowers CR
  • T-cell Lymphoma Epidemiology: the Known and Unknown.
    Curr Hematol Malig Rep Volume: 11 Page(s): 492 - 503
    12/01/2016 Authors: Phan A; Veldman R; Lechowicz MJ
  • Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Szary syndrome.
    Leuk Lymphoma Volume: 57 Page(s): 2813 - 2819
    12/01/2016 Authors: Danish HH; Liu S; Jhaveri J; Flowers CR; Lechowicz MJ; Esiashvili N; Khan MK
  • Human immunodeficiency virus lymphomas in the era of antiretrovirals: Is it finally time to change the discussion?
    Cancer Volume: 122 Page(s): 2621 - 2623
    09/01/2016 Authors: Gunthel CJ; Lechowicz MJ
  • US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.
    J Clin Oncol Volume: 34 Page(s): 2020 - 2027
    06/10/2016 Authors: Press OW; Li H; Schder H; Straus DJ; Moskowitz CH; LeBlanc M; Rimsza LM; Bartlett NL; Evens AM; Mittra ES
  • CD30+ Cutaneous T Cell Lymphoma: Response to Rotational Total Skin Electron Irradiation.
    Dermatol Ther (Heidelb) Volume: 6 Page(s): 251 - 263
    06/01/2016 Authors: Danish HH; Heumann TR; Bradley KT; Switchenko J; Esiashvili N; Lechowicz MJ; Flowers CR; Khan MK
  • A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
    Volume: 172 Page(s): 535 - 544
    02/01/2016 Authors: Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B
  • Complex Karyotype in Mantle Cell Lymphoma (MCL) Is Associated with Inferior Progression-Free Survival in Patients (pts) Receiving R-Hypercvad Followed By Autologous Stem Cell Transplant
    Volume: 126
    12/03/2015 Authors: Lee MJ; Switchenko J; Thomas JS; Koff JL; Nastoupil L; Lechowicz MJ; Langston AA; Flowers C; Cohen JB
  • Suvmax in 18-Fluorodeoxyglucose PET/CT Potentially Predict the Estimation of a Positive Biopsy in Cases of Lymphoma
    Volume: 126
    12/03/2015 Authors: Chandra P; Akinbobuyi O; Liao A; Arora J; Chen Z; Lechowicz MJ; Langston AA; Kowalsky J; Cohen JB; Flowers CR
  • A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma.
    Volume: 171 Page(s): 539 - 546
    11/01/2015 Authors: Cohen JB; Switchenko JM; Koff JL; Sinha R; Kaufman JL; Khoury HJ; Bumpers N; Colbert A; Hutchison-Rzepka A; Nastoupil LJ
  • Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
    Transfusion Volume: 55 Page(s): 2351 - 2357
    10/01/2015 Authors: Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C
  • Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 15 Page(s): 514 - 518
    09/01/2015 Authors: Cohen JB; Bucur S; Winton EF; Sinha R; Heffner LT; King N; Lonial S; Langston AA; Waller EK; Hutchison-Rzepka A
  • Clinical development of siltuximab.
    Curr Oncol Rep Volume: 17 Page(s): 29
    07/01/2015 Authors: Davis CC; Shah KS; Lechowicz MJ
  • Total skin electron therapy for cutaneous T-cell lymphoma using a modern dual-field rotational technique.
    Int J Radiat Oncol Biol Phys Volume: 92 Page(s): 183 - 191
    05/01/2015 Authors: Heumann TR; Esiashvili N; Parker S; Switchenko JM; Dhabbaan A; Goodman M; Lechowicz MJ; Flowers CR; Khan MK
  • Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma.
    Leuk Lymphoma Volume: 56 Page(s): 383 - 389
    02/01/2015 Authors: Nastoupil LJ; Shenoy PJ; Ambinder A; Koff JL; Nooka AK; Waller EK; Langston A; Seward M; Kaufman JL; Bernal-Mizrachi L
  • The use of trimethoprim and sulfamethoxazole (TMP-SMX) in dermatology.
    Folia Med Cracov Volume: 55 Page(s): 35 - 41
    01/01/2015 Authors: Michaek K; Lechowicz M; Pastuszczak M; Wojas-Pelc A
  • Risk Factors for Development of Myeloma: Role of Smoking and Alcohol
    Volume: 124
    12/06/2014 Authors: Nooka AK; Lonial S; Boise LH; Lechowicz MJ; Chen E
  • Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome.
    Bone Marrow Transplant Volume: 49 Page(s): 1360 - 1365
    11/01/2014 Authors: Lechowicz MJ; Lazarus HM; Carreras J; Laport GG; Cutler CS; Wiernik PH; Hale GA; Maharaj D; Gale RP; Rowlings PA
  • Total Skin Electron Irradiation (TSEI) Using Rotational Technique for Cutaneous T-Cell Lymphoma
    Volume: 90 Page(s): S680 - S681
    09/01/2014 Authors: Heumann TR; Esiashvili N; Parker S; Switchenko JM; Lechowicz M; Flowers C; Khan MK
  • Breast Implant-Associated Anaplastic Large Cell Lymphoma: Report of 2 Cases and Review of the Literature.
    Aesthet Surg J Volume: 34 Page(s): 884 - 894
    08/01/2014 Authors: Hart AM; Lechowicz MJ; Peters KK; Holden J; Carlson GW
  • Right ventricular myocarditis and its deceptive electrical signal.
    Int J Cardiol Volume: 175 Page(s): e16 - e18
    07/15/2014 Authors: Strickland PT; Hartlage GR; Lechowicz MJ; Clements SD
  • Simplified Technique for Administration of High Dose Melphalan
    Volume: 20 Page(s): S291 - S292
    02/01/2014 Authors: Hutcherson D; Valla K; Shah KS; Surati M; French K; Nooka A; Kaufman J; Lonial S; Cohen JB; Langston A
  • Favorable impact of pre-transplant ATG on outcomes of reduced-intensity hematopoietic cell transplants from partially mismatched unrelated donors.
    Bone Marrow Transplant Volume: 49 Page(s): 185 - 189
    02/01/2014 Authors: Langston AA; Prichard JM; Muppidi S; Nooka A; Lechowicz MJ; Lonial S; Sinha R; Graiser M; Kaufman JL; Khoury HJ
  • Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma.
    Clin Lymphoma Myeloma Leuk Volume: 13 Page(s): 657 - 663
    12/01/2013 Authors: Sinha R; Shenoy PJ; King N; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman J; Heffner LT
  • Breast Implant-Associated Anaplastic Large Cell Lymphoma: Treatment Experience In 53 Patients
    Volume: 122
    11/15/2013 Authors: Hart A; Lechowicz MJ
  • Hospitalization Outcome Metrics Based On Payer Status In Myeloma Patients That Receive Autologous Stem Cell Transplant (ASCT)
    Volume: 122
    11/15/2013 Authors: Gowda S; Langston A; Kaufman JL; Shah NN; Lechowicz MJ; Boise LH; Lonial S; Nooka AK
  • Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma.
    Biol Blood Marrow Transplant Volume: 19 Page(s): 1393 - 1395
    09/01/2013 Authors: Harvey RD; Kaufman JL; Johnson HR; Nooka A; Vaughn L; Flowers CR; Khoury HJ; Lechowicz MJ; Langston AA; Lonial S
  • Incidence and survival patterns of cutaneous T-cell lymphomas in the United States.
    Leuk Lymphoma Volume: 54 Page(s): 752 - 759
    04/01/2013 Authors: Imam MH; Shenoy PJ; Flowers CR; Phillips A; Lechowicz MJ
  • Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trial.
    Biol Blood Marrow Transplant Volume: 19 Page(s): 460 - 467
    03/01/2013 Authors: Lonial S; Akhtari M; Kaufman J; Torre C; Lechowicz MJ; Flowers C; Sinha R; Khoury HJ; Langston AA; Waller EK
  • Results of a Phase 2 Clinical Trial Testing the Efficacy of Plerixafor in Combination with Chemotherapy in the Mobilization of Autologous Blood Hematopoietic Progenitor Cells
    Volume: 19 Page(s): S191 - S191
    02/01/2013 Authors: Waller EK; Johnson HR; Jagirdar N; Gaylor C; Lipscomb C; Flowers C; Kaufman J; Khoury HJ; Langston A; Lechowicz M
  • Examining racial differences in diffuse large B-cell lymphoma presentation and survival.
    Leuk Lymphoma Volume: 54 Page(s): 268 - 276
    02/01/2013 Authors: Flowers CR; Shenoy PJ; Borate U; Bumpers K; Douglas-Holland T; King N; Brawley OW; Lipscomb J; Lechowicz MJ; Sinha R
  • A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma.
    Transfusion Volume: 53 Page(s): 76 - 84
    01/01/2013 Authors: Kaufman JL; Flowers CR; Rados KD; Calandra GB; Vose JM; Hewes LB; Lonial S; Langston AA; Khoury HJ; Lechowicz MJ
  • Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry
    Volume: 120
    11/16/2012 Authors: Hailemichael E; Kaufman JL; Flowers CR; Waller EK; Lechowicz MJ; Langston A; Graiser M; Boise LH; Lonial S; Nooka AK
  • Do Elderly Myeloma Patients Benefit From High Dose Therapy (HDT) and Autologous Stem Cell Transplant (ASCT)?: A Comparative Survival Analysis using SEER Registry
    Volume: 120
    11/16/2012 Authors: Hailemichael E; Kaufman JL; Flowers CR; Waller EK; Lechowicz MJ; Langston A; Graiser M; Boise LH; Lonial S; Nooka AK
  • Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase.
    Br J Haematol Volume: 158 Page(s): 608 - 614
    09/01/2012 Authors: Muringampurath-John D; Jaye DL; Flowers CR; Saxe D; Chen Z; Lechowicz MJ; Weisenburger DD; Bast M; Arellano ML; Bernal-Mizrachi L
  • A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
    Cancer Volume: 118 Page(s): 3538 - 3548
    07/15/2012 Authors: Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT
  • Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
    Blood Volume: 119 Page(s): 4115 - 4122
    05/03/2012 Authors: Horwitz SM; Kim YH; Foss F; Zain JM; Myskowski PL; Lechowicz MJ; Fisher DC; Shustov AR; Bartlett NL; Delioukina ML
  • Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma.
    Leuk Lymphoma Volume: 53 Page(s): 725 - 727
    04/01/2012 Authors: Muringampurath-John D; Flowers CR; Toscano M; Zhengjia C; Kaufman JL; Arellano M; Bernal-Mizrachi L; Heffner LT; Lechowicz M-J; McLemore M
  • Management of the cutaneous peripheral T-cell lymphomas: when subtypes matter.
    Cancer J Volume: 18 Page(s): 439 - 444
    01/01/2012 Authors: Choi MY; Lechowicz MJ
  • Clinical use of rituximab in patients with HIV related lymphoma and Multicentric Castleman's disease.
    Curr Drug Deliv Volume: 9 Page(s): 41 - 51
    01/01/2012 Authors: Reid E; Nooka A; Blackmon J; Lechowicz MJ
  • Vinorelbine, Paclitaxel, Etoposide, Cisplatin and Cytarabine (VTEPA) Is An Effective Salvage Therapy for Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) but Not for R/R Diffuse Large B Cell Lymphoma (DLBCL)
    Volume: 118 Page(s): 707 - 708
    11/18/2011 Authors: Sinha R; King N; Shenoy PJ; Lechowicz MJ; Bumpers K; Hutcherson D; Arellano M; Langston A; Kaufman JL; Heffner LT
  • Equivalent Survival Following Fludarabine/Melphalan Reduced Intensity Conditioning with or without Rabbit ATG As Part of GvHD Prophylaxis
    Volume: 118 Page(s): 855 - 856
    11/18/2011 Authors: Prichard JM; Muppidi S; Flowers CR; Kaufman JL; Lechowicz MJ; Lonial S; Nooka AK; Sinha R; Waller EK; Langston A
  • Temporal Changes in Plerixafor Administration Do Not Impact Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial
    Volume: 118 Page(s): 1287 - 1288
    11/18/2011 Authors: Harvey RD; Lonial S; Renfroe H; Sinha R; Flowers CR; Lechowicz MJ; Khoury HJ; Langston A; Waller EK; Kaufman JL
  • Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Transfusion Volume: 51 Page(s): 2175 - 2182
    10/01/2011 Authors: Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C
  • A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation.
    Transfusion Volume: 51 Page(s): 1779 - 1783
    08/01/2011 Authors: Renfroe H; Arnold M; Vaughn L; Harvey RD; Hamilton E; Lonial S; Khoury HJ; Kaufman JL; Lechowicz MJ; Flowers CR
  • Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
    J Clin Oncol Volume: 29 Page(s): 1182 - 1189
    03/20/2011 Authors: O'Connor OA; Pro B; Pinter-Brown L; Bartlett N; Popplewell L; Coiffier B; Lechowicz MJ; Savage KJ; Shustov AR; Gisselbrecht C
  • Stem cell transplantation as a biological therapy for peripheral T-cell lymphomas.
    Expert Opin Biol Ther Volume: 11 Page(s): 31 - 40
    01/01/2011 Authors: Abouyabis AN; Shenoy PJ; Lechowicz MJ; Flowers CR
  • A Systematic Review and Meta-Analysis of Front-line Anthracycline-Based Chemotherapy Regimens for Peripheral T-Cell Lymphoma.
    ISRN Hematol Volume: 2011 Page(s): 623924
    01/01/2011 Authors: Abouyabis AN; Shenoy PJ; Sinha R; Flowers CR; Lechowicz MJ
  • Pralatrexate Is Effective In Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL) with Prior Ifosfamide, Carboplatin, and Etoposide (ICE)-Based Regimens
    Volume: 116 Page(s): 731 - 732
    11/19/2010 Authors: Goy A; Pro B; Savage KJ; Bartlett NL; Lechowicz MJ; Jacobsen ED; Young F; Crump M; Borghaei H; Link B
  • Use of Rituximab with CHOP Chemotherapy Appears to Overcome Racial Disparities In Survival In Black Patients with Diffuse Large B Cell Lymphoma When Compared to CHOP Chemotherapy Alone.
    Volume: 116 Page(s): 650 - 650
    11/19/2010 Authors: Borate U; Shenoy PJ; Donnellan W; Bumpers K; Douglas-Holland T; King N; Lechowicz MJ; The A; Jaye DL; Reddy V
  • Examining the Racial Disparities In Presentation and Treatment for Patients with Diffuse Large B-Cell Lymphoma (DLBCL).
    Volume: 116 Page(s): 647 - 647
    11/19/2010 Authors: Shenoy PJ; Borate U; Bumpers K; Douglas-Holland T; King N; Lechowicz MJ; Jaye DL; Donnellan W; The A; Reddy V
  • Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study.
    Volume: 116 Page(s): 1154 - 1155
    11/19/2010 Authors: Horwitz SM; Kim YH; Foss FM; Zain JM; Myskowski P; Lechowicz MJ; Fisher DC; Shustov A; Bartlett NL; Delioukina ML
  • Allogeneic Hematopoietic Cell Transplantation (AHCT) for Primary Cutaneous T Cell Lymphoma (CTCL): a Center for International Blood and Marrow Transplant Research (CIBMTR) Review
    Volume: 116 Page(s): 165 - 165
    11/19/2010 Authors: Lechowicz MJ; Agovi M; Carreras J; Lazarus HM; Laport GG; Montoto S; Maloney DG; Hari P
  • Cost-Effectiveness Analysis of a "Just-In-Time" Strategy of Salvage Plerixafor Administration for Poor-Mobilizing Patients Undergoing Autologous Transplant.
    Volume: 116 Page(s): 923 - 924
    11/19/2010 Authors: Li J; Hamilton E; Vaughn L; Graiser M; Repfroe H; Kaufman JL; Lonial S; Flowers CR; Lechowicz MJ; Langston A
  • Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease.
    Transfusion Volume: 50 Page(s): 2424 - 2431
    11/01/2010 Authors: Akhtari M; Giver CR; Ali Z; Flowers CR; Gleason CL; Hillyer CD; Kaufman J; Khoury HJ; Langston AA; Lechowicz MJ
  • A phase I/II trial combining high-dose melphalan and autologous transplant with bortezomib for multiple myeloma: a dose- and schedule-finding study.
    Clin Cancer Res Volume: 16 Page(s): 5079 - 5086
    10/15/2010 Authors: Lonial S; Kaufman J; Tighiouart M; Nooka A; Langston AA; Heffner LT; Torre C; McMillan S; Renfroe H; Harvey RD
  • Deep venous thromboses in patients with hematological malignancies after peripherally inserted central venous catheters.
    Leuk Lymphoma Volume: 51 Page(s): 1473 - 1477
    08/01/2010 Authors: Tran H; Arellano M; Chamsuddin A; Flowers C; Heffner LT; Langston A; Lechowicz MJ; Tindol A; Waller E; Winton EF
  • Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits?
    Clin Lymphoma Myeloma Leuk Volume: 10 Page(s): 270 - 277
    08/01/2010 Authors: Shenoy P; Sinha R; Tumeh JW; Lechowicz MJ; Flowers CR
  • A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma.
    Am J Clin Pathol Volume: 133 Page(s): 718 - 726
    05/01/2010 Authors: Schniederjan SD; Li S; Saxe DF; Lechowicz MJ; Lee KL; Terry PD; Mann KP
  • Nasal NK/T-cell lymphoma: where are we now?
    Oncology (Williston Park) Volume: 24 Page(s): 362 - 363
    04/15/2010 Authors: Lechowicz MJ
  • Nasal NK/T-cell Lymphoma: Where Are We Now? The Au Article Reviewed
    ONCOLOGY-NEW YORK Volume: 24 Page(s): 362 - 363
    04/01/2010 Authors: Lechowicz MJ
  • Update on HHV-8-Associated Malignancies.
    Curr Infect Dis Rep Volume: 12 Page(s): 147 - 154
    03/01/2010 Authors: Sunil M; Reid E; Lechowicz MJ
  • HIV-K: an integrative knowledge base for semantic integration of AIDS-related malignancy data and treatment outcomes.
    Stud Health Technol Inform Volume: 159 Page(s): 239 - 243
    01/01/2010 Authors: Tirado-Ramos A; Saltz J; Lechowicz MJ
  • Molecular and clinical assessment in the treatment of AIDS Kaposi sarcoma with valproic Acid.
    Clin Infect Dis Volume: 49 Page(s): 1946 - 1949
    12/15/2009 Authors: Lechowicz M; Dittmer DP; Lee JY; Krown SE; Wachsman W; Aboulafia D; Dezube BJ; Ratner L; Said J; Ambinder RF
  • Prognostic Significance of Circulating Lymphoma Cells in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
    Volume: 114 Page(s): 1151 - 1152
    11/20/2009 Authors: Muringampurath-John D; Flowers CR; Jabbar AA; Sinha R; Arellano M; Bernal-Mizrachi L; Kaufman JL; Jaye DL; Chen Z; Lechowicz MJ
  • The Combination of Romidepsin and Bortezomib Results in Synergistic Induction of Apoptosis in Human B-Lymphoma Cell Lines.
    Volume: 114 Page(s): 673 - 673
    11/20/2009 Authors: Deshpande SS; Lechowicz MJ; Sinha R; Kaufman JL; Boise LH; Lonial S; Flowers CR
  • HIV Related Hodgkin's Lymphoma in the HAART Era: A Comprehensive Review and Meta-Analysis of Response and Survival Rates.
    Volume: 114 Page(s): 659 - 660
    11/20/2009 Authors: Sunil M; Mixon T; Reid E; Lechowicz MJ
  • Spectrum of FDG PET/CT findings in Burkitt lymphoma.
    Clin Nucl Med Volume: 34 Page(s): 355 - 358
    06/01/2009 Authors: Zeng W; Lechowicz MJ; Winton E; Cho S-M; Galt JR; Halkar R
  • PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)
    Volume: 27
    05/20/2009 Authors: O'Connor O; Pro B; Pinter-Brown L; Popplewell L; Bartlett N; Lechowicz M; Savage K; Coiffier B; Saunders M; Horwitz S
  • PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
    J Clin Oncol Volume: 27 Page(s): 8561
    05/20/2009 Authors: O'Connor O; Pro B; Pinter-Brown L; Popplewell L; Bartlett N; Lechowicz M; Savage K; Coiffier B; Saunders M; Horwitz S
  • A Randomized Phase I Study of Melphalan and Bortezomib for Autologous Transplant in Myeloma
    CLINICAL LYMPHOMA & MYELOMA Volume: 9 Page(s): S60 - S60
    02/01/2009 Authors: Kaufman JL; Lonial S; Sinha R; Torre C; Langston AA; Lechowicz MJ; Flowers C; McMillan S; Renfroe H; Heffner LT
  • PHARMACOKINETIC (PK) COMPARISON OF INTRAVENOUS VERSUS ORAL BUSULFAN CONDITIONING REGIMENS FOR ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS) PATIENTS
    Volume: 15 Page(s): 154 - 155
    02/01/2009 Authors: Hutcherson DA; Surati M; Sanvidge K; Harvey D; Al-Baldawi RN; Langston A; Flowers C; Lonial S; Kaufman J; Lechowicz MJ
  • EXTRACORPOREAL PHOTOPHERESIS THERAPY FOR CHRONIC GRAFT-VERSUS-HOST DISEASE: RESPONSE IS ASSOCIATED WITH CONTENT OF DENDRITIC CELLS AND T-CELLS IN PERIPHERAL BLOOD AT INITIATION OF TREATMENT
    Volume: 15 Page(s): 128 - 129
    02/01/2009 Authors: Akhtari M; Giver CR; Renfroe HM; Langston AA; Khoury HJ; Flowers CR; Kaufman JL; Lonial S; Lechowicz MJ; Gleason CL
  • A Novel Flow Cytometric Antibody Panel for Distinguishing Burkitt Lymphoma from CD10-Positive Diffuse Large B-Cell Lymphoma
    Volume: 89 Page(s): 285A - 285A
    01/01/2009 Authors: Schniederjan SD; Li S; Lechowicz MJ; Saxe DF; Terry PD; Mann KP
  • A Novel Flow Cytometric Antibody Panel for Distinguishing Burkitt Lymphoma from CD10-Positive Diffuse Large B-Cell Lymphoma
    Volume: 22 Page(s): 285A - 285A
    01/01/2009 Authors: Schniederjan SD; Li S; Lechowicz MJ; Saxe DF; Terry PD; Mann KP
  • Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study
    Volume: 112 Page(s): 1247 - 1247
    11/16/2008 Authors: Langston AA; Murali S; McMillan S; Heffner LT; Lonial S; Waller EK; Flowers CR; Kaufman J; McLemore ML; Sinha R
  • Higher Numbers of Circulating Dendritic Cells and T-Cells Predict Response to Extracorporeal Photopheresis in Patients with Chronic Graft-Versus-Host Disease
    Volume: 112 Page(s): 432 - 432
    11/16/2008 Authors: Giver CR; Akhtari M; Langston AA; Khoury HJ; Flowers CR; Kaufman JL; Lonial S; Lechowicz MJ; Gleason CL; Vaughn ML
  • A Randomized Phase I Trial of Melphalan plus Bortezomib as Conditioning for Autologous Transplant for Myeloma: The Effect of Sequence of Administration
    Volume: 112 Page(s): 1144 - 1145
    11/16/2008 Authors: Lonial S; Kaufman J; Torre C; Langston A; Lechowicz MJ; Flowers C; McMillan S; Renfroe H; Heffner LT; Waller EK
  • PROPEL: A Multi-Center Phase 2 Open-Label Study of Pralatrexate (PDX) with Vitamin B-12 and Folic Acid Supplementation in Patients with Replapsed or Refractory Peripheral T-Cell Lymphoma
    Volume: 112 Page(s): 103 - 103
    11/16/2008 Authors: O'Connor OA; Pro B; Pinter-Brown L; Popplewell L; Barlett N; Shustov A; Lechowicz MJ; Savage KJ; Coiffier B; Jacobsen E
  • Pralatrexate (PDX) IS Active in Cutaneous T-Cell Lymphoma: Preliminary Results of a Multi-Center Dose-Finding Trial
    Volume: 112 Page(s): 556 - 557
    11/16/2008 Authors: Horwitz SM; Duvic M; Kim Y; Zain JM; Lechowicz MJ; Myskowski P; Weissbrot H; Wright D; Chance L; Koutsoukos T
  • Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States.
    Leuk Lymphoma Volume: 49 Page(s): 2099 - 2107
    11/01/2008 Authors: Abouyabis AN; Shenoy PJ; Lechowicz MJ; Flowers CR
  • Long-term progression-free survival after early autologous transplantation for mantle-cell lymphoma.
    Bone Marrow Transplant Volume: 42 Page(s): 529 - 534
    10/01/2008 Authors: Murali S; Winton E; Waller EK; Heffner LT; Lonial S; Flowers C; Kaufman J; Arellano M; Lechowicz MJ; Mann KP
  • A randomized phase I trial of Melphalan plus Bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration
    Volume: 110 Page(s): 288A - 289A
    11/16/2007 Authors: Lonial S; Kaufman J; Langston A; Heffner LT; Torre C; Lechowicz MJ; Flowers C; McMillan S; Arnold M; Waller NK
  • The effect of rituximab on mobilization with AMD3100 plus G-CSF in patients with relapsed or refractory NHL or HD
    Volume: 110 Page(s): 568A - 568A
    11/16/2007 Authors: Kaufman JL; Cook AM; Flowers C; Langston AA; Lonial S; Lechowicz MJ; Khoury HJ; Calandra G; Waller N
  • Therapeutic drug monitoring (TDM) of IV busulfan in patients with severe obesity
    Volume: 110 Page(s): 592A - 592A
    11/16/2007 Authors: Hutcherson DA; Sessions JK; Mihelic RA; Sanvidge K; Stricker SR; Langston A; Flowers C; Lechowicz MJ; Waller N; Lonial S
  • Patulin, a mycotoxin, has potent cytotoxic activity on actue lymphoblastic leukemia and induce apoptosis through intrinsic and extrinsic pathways
    Volume: 110 Page(s): 151B - 152B
    11/16/2007 Authors: Wang F; David E; Lonial S; Arellano M; Khoury HJ; Langston A; Lechowicz MJ; Waller N
  • A pilot trial of valproic acid in patients with Kaposi's sarcoma: A multi-center trial of the AIDS malignancy consortium
    Volume: 110 Page(s): 676A - 676A
    11/16/2007 Authors: Lechowicz MJ; Lee J; Dittmer D; Krown S; Said J; Ambinder RF
  • A randomized phase I trial of melphalan plus bortezomib as conditioning for autologous transplant for myeloma: The effect of sequence of administration
    Volume: 13 Page(s): 56 - 56
    02/01/2007 Authors: Lonial S; Kaufman J; Langston AA; Khoury HJ; Torre C; Lechowicz MJ; Flowers C; Waller EK
  • A randomized trial to evaluate the impact of cytokines (G-CSF or GM plus G-CSF) on dendritic cell and T-Cell content and function when mobilizing normal donors for allogeneic progenitor cell transplant.
    Volume: 108 Page(s): 964A - 964A
    11/16/2006 Authors: Lonial S; McMillan S; Torre C; Langston AA; Hamilton E; Cook A; Flowers C; Kaufman JL; Lechowicz MJ; Waller N
  • Infliximab for the treatment of chronic graft versus host disease.
    Volume: 108 Page(s): 818A - 818A
    11/16/2006 Authors: Tolbert E; Waller N; Khoury HJ; Lechowicz MJ; Flowers C; Lonial S; Vann L; Langston A; Kaufman JL
  • T cell reconstitution in first 200 days post transplantation predicts long term survival in allogeneic hematopoetic progenitor cell transplantation (HPCT).
    Volume: 108 Page(s): 920A - 920A
    11/16/2006 Authors: Vann L; Larks M; Flowers C; Lonial S; Kaufman J; Lechowicz MJ; Langston AA; Khoury J; Waller N
  • Benefits of CHOP-14 followed by transplantation in patients with peripheral T-cell lymphoma.
    Volume: 108 Page(s): 254B - 254B
    11/16/2006 Authors: Abouyabis AN; Lechowicz M; Mann K; Heffner LT; Winton E; Bucur S; Flowers CR
  • Impact of revised international working group criteria on lymphoma patients undergoing autologous stem cell transplantation.
    Volume: 108 Page(s): 873A - 873A
    11/16/2006 Authors: Lucas AS; Flowers C; Langston A; Lonial S; Lechowicz MJ; Waller N; Kaufman JL; Jean Khoury H
  • Patients receiving patifermin in conjunction with melphalan 200 required fewer platelet transfusions: Analysis of a retrospective cohort study.
    Volume: 108 Page(s): 407B - 407B
    11/16/2006 Authors: Hutcherson DA; Langston A; Lin CH; Flowers C; Lechowicz MJ; Waller N; Sessions JK; Kaufman JL; Jean Khoury H; Lonial S
  • Tolerability and anti-leukemic activity of ara-C, topotecan, and gemtuzumab ozogamicin [ATGO] in advanced MDS and AML: Interim analysis of phase I/II data.
    Volume: 108 Page(s): 554A - 554A
    11/16/2006 Authors: Murali S; Winton EF; McMillan S; Lonial S; Waller N; Heffner L; Flowers C; Kaufman JL; Lechowicz MJ; Khoury HJ
  • Phase II study of denileukin diftitox (ONTAK (R)) in patients with relapsed/refractory B-cell Non-Hodgkin's lymphoma (B-NHL) and poor bone marrow reserve.
    Volume: 108 Page(s): 263B - 264B
    11/16/2006 Authors: Czuczman MS; Pinter-Brown L; Lechowicz MJ; Bartlett N; Lazarus H; Lister J; Goy A; Kahanic S; Rosen P; Acosta M
  • Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: implications for consolidation radiotherapy.
    Int J Radiat Oncol Biol Phys Volume: 66 Page(s): 961 - 965
    11/15/2006 Authors: Kahn ST; Flowers C; Lechowicz MJ; Hollenbach K; Johnstone PAS
  • Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.
    Leuk Lymphoma Volume: 47 Page(s): 2155 - 2162
    10/01/2006 Authors: Lonial S; Arellano M; Hutcherson D; Langston A; Flowers C; Heffner LT; Winton E; Jo Lechowicz M; Waller EK
  • Presentation of primary hepatic lymphoma (PHL) as episodic jaundice
    Volume: 101 Page(s): S345 - S345
    09/01/2006 Authors: Mittal V; Moreira R; Lechowicz MJ
  • A randomized phase I trial of melphalan + bortezomib as conditioning for autologous transplant for myeloma.
    J Clin Oncol Volume: 24 Page(s): 17550
    06/20/2006 Authors: Kaufman JL; Waller EK; Torre C; McMillan S; Langston A; Flowers C; Lechowicz M; Tighiouart M; Lonial S
  • Idiopathic secondary post-transplant thrombocytopenia (ISPT) following autologous hematopoietic progenitor cell transplantation (HPCT) is associated with transplantation of lower numbers of primitive hematopoietic progenitors
    Volume: 12 Page(s): 132 - 132
    02/01/2006 Authors: Ninan MJ; Arellano M; Philip A; Langston A; Flowers CR; Lonial S; Kaufman J; Lechowicz M; Khoury JH; Roback J
  • Patient characteristics in CD 20(+) and CD 20(-) adult acute lymphoblastic leukemia (ALL): A single institution analysis.
    Volume: 106 Page(s): 210B - 210B
    11/16/2005 Authors: Gladney SP; Heffner LT; Langston A; Holden J; Phillips C; Winton E; Flowers CR; Lechowicz MJ; Lonial S; Waller E
  • Systematic review and meta-analysis of radioimmunotherapy regimens in patients with relapsed follicular and transformed nonhodgkins lymphomas.
    Volume: 106 Page(s): 870A - 871A
    11/16/2005 Authors: Orina JN; Moore SG; Lechowicz MJ; Flowers CR
  • A randomized trial to evaluate the impact of cytokines (G-CSF or GM plus GCSF) on dendritic cell and T-cell content and function when mobilizing normal donors for allogeneic progenitor cell transplant
    Volume: 106 Page(s): 555A - 555A
    11/16/2005 Authors: Lonial S; Torre C; Langston AA; McMillans S; Hamilton E; Flowers C; Lechowicz MJ; Waller EK
  • Determining the benefits of chemotherapy for achieving complete response in patients with untreated advanced stage follicular lymphoma: A systematic review and meta-analysis.
    Volume: 106 Page(s): 88A - 89A
    11/16/2005 Authors: Orina JN; Moore SG; Lechowicz MJ; Flowers CR
  • Effects of mycotoxins on mononuclear cells (MNCs) in normal blood, T-cell leukemia and lymphoma cell lines.
    Volume: 106 Page(s): 287B - 287B
    11/16/2005 Authors: Klein KR; Woodward CS; Waller EK; Lechowicz MJ; Rosenthal H
  • Rituximab does not inhibit chemo-mobilization of HPC or engraftment following autologous transplant for lymphoma
    Volume: 11 Page(s): 6 - 6
    02/01/2005 Authors: Kaufman JL; Lonial S; Hicks M; Langston A; Flowers C; Lechowicz MJ; Khoury H; Waller EK
  • Refractory or relapsed Hodgkin's disease and non-Hodgkin's lymphoma: optimizing involved-field radiotherapy in transplant patients.
    Cancer J Volume: 11 Page(s): 425 - 431
    01/01/2005 Authors: Kahn ST; Flowers CR; Lechowicz MJ; Hollenbach K; Johnstone PAS
  • Value of PET restaging after chemotherapy for non-Hodgkins lymphoma: Implications for consolidation radiotherapy
    Volume: 63 Page(s): S422 - S422
    01/01/2005 Authors: Kahn S; Koshy M; Flowers C; Lechowicz M; Hollenbach K; Johnstone PA
  • A randomized trial to evaluate the impact of cytokines on dendritic cell, T-cell and T-cell function when mobilizing normal donors for allogeneic progenitor cell transplant: An interim analysis.
    Volume: 104 Page(s): 780A - 780A
    11/16/2004 Authors: Lonial S; Torre C; Hicks M; Mcmillan S; Langston AA; Flowers CR; Lechowicz MJ; Waller EK
  • Predictors of more rapid lymphoid reconstitution after allogeneic transplantation
    Volume: 104 Page(s): 864A - 864A
    11/16/2004 Authors: Arellano ML; Moore SG; Kudchadkar R; Flowers CR; Langston AA; Lonial S; Lechowicz MJ; Waller EK
  • A phase I trial of ara-C, topotecan, and gemtuzumab ozogamicin (Mylotarg (R)) for advanced MDS and secondary or relapsed AML.
    Volume: 104 Page(s): 502A - 502A
    11/16/2004 Authors: Langston AA; McMillan S; Lonial S; Smith K; Waller EK; Heffner LT; Bucur S; Redei I; Flowers C; Lechowicz MJ
  • Phase II study of ProMACE-CytaBOM with trimetboprim sulfametboxazole, granulocyte colony stimulating factor (GCSF) and antiretroviral therapy in patients with AIDS related non Hodgkin's lymphoma (AIDS-NHL), (S9320).
    Volume: 102 Page(s): 403A - 403A
    11/16/2003 Authors: Swinnen LJ; Gaynor E; LeBlanc M; Lechowicz MJ; Unger J; Miller TP; Grogan TA; Fisher RI
  • Epstein-Barr virus DNA in body fluids.
    Curr Opin Oncol Volume: 14 Page(s): 533 - 537
    09/01/2002 Authors: Lechowicz MJ; Lin L; Ambinder RF
  • Rugby injuries.
    Am J Emerg Med Volume: 16 Page(s): 327 - 328
    05/01/1998 Authors: Richman PB; Brogan GX; Lechowicz MJ
Read more publications Fewer publications
Education
  • Educational Programs
    • Doctor of Medicine (MD)
    • MD and Bioethics (MA) Dual Degree
    • MD and Public Health (MPH) Dual Degree
    • MD and Master of Science in Clinical Research (MSCR) Dual Degree
    • MD and Business (MBA) Dual Degree
    • Education Transformation
  • Admissions
    • Visiting Medical Students
    • International Students
  • Cost and Financial Aid
  • Resources
    • Center for Holistic Student Success
    • Office of Multicultural Affairs
    • Academic Advising
    • Registrar
  • Residencies and Fellowships
    • Programs
    • Housestaff
    • Wellness
    • Diversity
  • Office of Postdoctoral and Mentored Trainee Education (OPMTE)
    • FIRST IRACDA Program
    • Prospective Postdocs
    • Career and Professional Development
    • Training Programs at Emory
    • Featured Alumni
  • Office of Multicultural Affairs
    • Meet Our Team
    • Emory Pipeline Collaborative
    • Emory Premedical Readiness Engagement Program
    • EMPACT Mentoring Program
    • HealthPREP
    • HCOP Ambassadors
    • Summer Science Academy
    • OMA Events
    • Diversity, Equity & Inclusion for Residents & Fellows
  • Emory School of Medicine Simulation Program
    • Work with ExCEL
    • Simulation Program
  • Medical Scientist Training Program (MD/PhD)
    • Welcome
    • Who we are
    • Our Program
    • Admissions
    • Donate to MD/PhD Program
  • Center for Holistic Student Success
    • Academic Support
    • Well-being Resources
    • EmoryDOCS
    • Mental Health and Wellness
  • Center for Humanizing Innovations in Medical Education
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2024 Emory University
  • Privacy Policy
  • Emergency Information